Angiogenic factors in the pathogenesis and pathophysiology of preeclampsia: A Mini review

Suseela Yelumalai 3, Kaviarasan Subramanian 2, Siti Zawiah Omar 3, Rajes Qvist 2, Sekaran Mu- niandy 1*

1Department of Molecular Medicine, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia
2Department of Medicine, University of Malaya Medical Center, University of Malaya, 50603 Kuala Lumpur, Malaysia
3Department of Obstetrics & Gynaecology, University of Malaya Medical Center, University of Malaya, 50603 Kuala Lumpur, Malaysia

Abstract

Preeclampsia (PE) the de novo occurrence of hypertension and proteinuria after the 20th week of gestation is a major cause of maternal and fetal morbidity worldwide. While the etiology of PE is still unclear, clinical phenotypes have been associated with high circulating levels of anti-angiogenic proteins such as soluble Fms-like tyrosine kinase 1 (sFlt1) and soluble endoglin (sEng). Furthermore PE is associated with low serum free placental growth factor (PIGF) and free vascular endothelial growth factor (VEGF). Since alterations in levels of these factors precede the onset of clinical disease, have these factors may be useful to screen or identify patients at risk for PE. Women with a history of PE have an increased risk of hypertension, and cardiovascular and renal disease Therefore, this raises the possibility of measuring circulating angiogenic proteins in the blood and the urine as a diagnostic and screening tool for PE. The availability of a test to predict PE would be a powerful tool in preventing PE-induced mortality, especially in developing nations, where high-risk specialists are limited. This review will summarize our current understanding of the role of circulating angiogenic proteins in the pathogenesis and clinical diagnosis/prediction of PE.

Key words: Preeclampsia, angiogenic factors, hypertension, pathophysiology

Accepted March 11 2010

Introduction

Preeclampsia (PE) is a pregnancy induced hypertensive disorder that by usually affects 3% - 5% of first pregnancy and is a leading cause of maternal and fetal mortality. As many as 8,370,000 cases of PE per year are seen [1]. This disorder characterized by the development of a maternal syndrome that includes, proteinuria, haemolysis, liver abnormalities, thrombocytopenia (HELLP Syndrome), seizures (eclampsia) coagulations abnormalities, edema, and vascular abnormalities [2,3]. The underlying mechanism that places women with a history of PE at risk for hypertension and CVD remains speculative. In addition the etiology of PE remains largely unknown but it is known to be related to endothelial dysfunction. However, investigations on this disorder offer potential treatment for PE [5]. Therefore, decreased placental perfusion is not the primary root cause of PE [6]. Certain maternal factors genetically, medically or environmentally, may be present to increase the susceptibility of reduced placental perfusion have increasing the risk of the development of PE or other hypertensive disorders during pregnancy [7].

Genetic Factor

The genetic cause of PE is still unclear, and genes contributing linked to PE have yet to be elucidated. However, studies have reported an association between PE and polymorphisms of genes that control hypertension, coagulations or oxidative stress metabolism, such as rennin, angiotensinogen, endothelial nitric oxide synthase (eNOS), Factor V LEIDEN, methytrtetrahydrofolate or lipoprotein lipase [8-12]. A number of these factors are also associated with recurrent fetal loss [13,14] and emphasizes the contribution of PE to fetal loss. Thrombophilic mutations of the two vital thrombophilia markers, factor V Leiden (FVL) and prothrombin G20210A as a
genetic factor may contribute to PE which tends to pro-
gress into recurrent pregnancy loss among the Asian
population [15]. Most PE cases are seldom categorized as
hereditary disease. However first degree relative of a
women with PE are often at risk of this hypertensive disorder
depending on the severity of the disease [16].

**Maternal factors**

PE is categorized a disorder of the first pregnancy. How-
ever, investigations showed that multiparous women fre-
quently lost their protective factors from encountering PE
if their pregnancy is with a new partner and said to be at
risk similar to that of primiparous women [17]. The risk
of PE decreases as the women is continuously exposed to
specific antigens from the same partner. Although the
potential risk of PE on multiparity is reduced, interpreg-
nancy interval may lead to increased risk of encountering
this disease [18]. Pre-existing maternal factors such as
previous history of preeclampsia, multiple pregnancy, and
nulliparity were found to increase the risk of PE.

**Other Factors**

Insulin resistance, obesity and thrombophilia are the other
factors that influence PE [19-21]. Protein-calorie under
nutrition [22] is another important risk factor which has
been discovered in developing countries, and calcium
supplementation does not promote/initiate the increased
risk of preeclampsia [23]. Multifestal gestations and hy-
datidiform moles are also associated with increased pree-
clampsia risk [24].

**Pathogenesis and Pathophysiology of PE**

**Role of Placenta**

Vascularization is an important process which involves
vasculogenesis (formation of new blood vessel) and an-
giogenesis (formation of growth blood vessel) for a
proper formation and complete development of placenta
[25]. Defects in placental perfusion is an initial event in
PE leads to vascular endothelial dysfunction by the
mechanisms that remain unclear [26]. It has been sug-
gested that release of factors from the placenta in re-
sponse to ischemia results in dysfunction of the endothe-
lium of maternal circulation [27]. Studies using serum
from preeclamptic women have shown that cultured endo-
thelial cells respond with an increased expression and
release of growth factors and fibronectin, induction of
oxygen radicals, as well as an inhibition of prostacyclin
production [28, 29].

![Diagram](image)

**Figure 1. Endothelial dysfunction in preeclampsia**
The left panel shows condition in normal subjects while the right panel shows
situation in subjects with preeclampsia.

**Abnormal Placentation**

Normal placental development involves extravillous cyto-
trophoblastic invasion of the uterine spiral arteries of the
deciduas and myometrium. The invasive fetal cells re-
place the endothelial layer of uterine vessels, transforming
them from small resistant vessels to flaccid high caliber capacitance vessels (Fig.1). In PE, the increase in uterine blood flow needed to sustain the fetus through pregnancy is insufficient. Cytotrophoblast invasion of the arteries is limited to the superficial deciduas and the myometrial segments remain narrow [30]. Fisher et al shown that in normal placental development, invasive cytотrophoblasts downregulate the expression of adhesion molecules characteristics of their epithelial cell origin and adopt endothelial cell-surface adhesion phenotype, a process dubbed pseudovasculogenesis [31] or vascular mimicry. In PE, cytотrophoblast do not undergo this switching of cell-surface integrins and adhesion molecules, and they fail to adequately invade the myometrial spiral arteries.

**Endothelial dysfunction**

Endothelial dysfunction, a central component of the pathophysiology of PE, is known to contribute in the pathogenesis of hypertension and cardiovascular diseases. Hypertension associated with PE develops during pregnancy and remits after delivery, implicating the placenta as the central cause of the disease. Intact endothelial cells have antiadhesive and anticoagulant properties, regulate vascular permeability and modulate the effect of vasoconstrictor agonist on the vessel wall [32]. Several lines of evidence support the hypothesis that dysfunction of the vascular endothelium is important in the pathogenesis of PE [33]. The vascular response to vasoconstrictors, the tendency for coagulation [34], permeability of capillaries [35] and the plasma concentration of fibronectin and endothelin is greatly enhanced in preeclamptic women [36,37]. Although some studies have reported no significant changes in circulating levels of endothelin during pregnancy-induced hypertension, a role for endothelin as a paracrine or autocrine agent in PE remains worthy of consideration.

**Angiogenic Factors**

**Soluble Fms-like tyrosine Kinase-1, VEGF and PIGF**

Hypertension and proteinuria the hallmarks of PE, occur due to excess circulating anti-angiogenic peptides produced by the placenta, which is the soluble fms-like tyrosine kinase 1 (sFlt-1, also referred to as sVEGFR-1) (anti-angiogenic factors) [25]. In context to pro-angiogenic proteins such as vascular endothelial growth factor (VEGF) and placent growth factor (PIGF), the presence of sFlt-1 has been shown to cause hypertension, proteinuria and glomerular endotheliosis in rats [37]. Studies have shown that patient diagnosed with PE had an elevated level of sFlt-1 in maternal serum or plasma compared to the pro-angiogenic factors [25].

sFlt-1 a tyrosine kinase protein which disables blood vessel growth [38] and is an alternatively spliced variant of vascular endothelial growth factor receptor 1 (VEGF-R1). It acts as a VEGF and PIGF antagonist [39] by preventing the interaction of the pro-angiogenic factors with the endothelial receptors on the cell surface and induces endothelial dysfunction which subsequently leads to PE (Fig.2). Elevated levels of circulating angiogenic proteins/factors in the maternal serum or plasma in pregnancy would discriminate normal pregnancy from PE. Levels of sFlt-1 remain stable during gestational age of 16-20 weeks and increase steadily during the 24-28 weeks of gestation period until term [40]. In PE, the levels of sFlt-1 are found to be highly increased as compared to PIGF levels [25]. These data suggest that, sFlt-1 to PIGF ratio could be a predictive marker for the early onset of PE rather than measuring sFlt-1 or PIGF levels alone [41].

**Endoglin and Transforming Growth Factors**

Endoglin (ENG) also known as CD105 [42], was earlier discovered by a monoclonal antibody (44G4) raised against a pre-B lymphobalstic HOON cell line [43]. ENG encodes for type 1 integral membrane glycoprotein [44] and mutations in ENG cause an autosomal-dominant disorder disease known as hereditary haemorrhagic telangiectasia type 1 (HHT1), this disorder is characterized by arteriovenous malformations and focal loss of capillaries [45]. ENG functions as an receptor for several transforming growth factor super family members [46], ENG act as a protein modulator of TGF-β signaling by interaction with TGF-β1 and TGF-β2 [47]. It is identified as an accessory receptor for TGF-β as it plays a versatile role in tumor angiogenesis [45, 48]. In PE [42], focus on ENG is due to the fact that ENG has a major contribution to vasculogenesis and disease [49].

TGF-β a family of multifunctional proteins, includes three TGF-β isoforms (TGF-β1, TGF-β2 and TGF-β3), activins and bone morphogenetic proteins (BMP’s) which are involved in many different pathophysiological processes including development, wound healing, cancer, fibrosis, vascular, and immune disease [49, 50]. The signaling pathway plays a very important role in vascular morphogenesis as the investigation using targeted inactivation has shown. Signaling occurs via two transmembrane type I and type II receptors endowed with serine/threonine kinase activity [51, 52], TGF-β interacts with TGF-β type II receptor (TβRII) and TGF-β type I receptor (TβRI) also know as activin receptor-like kinase 5 (ALK-5) [53].

As an auxiliary receptor, [54] it act as signaling response modulator protein of multiple members of the TGF-β family [55] and involved in TGF-β independent signaling [56]. Furthermore, a soluble form of endoglin (sEng) has been found, most likely generated by proteolytic shedding, which antagonizes the membrane bound form [42]. Taken together, multiple layers of complexity exist by which the function of endoglin is regulated.
**Soluble Endoglin (sEng)**

Placental endoglin (ENG), a member of TGF-β family is found overexpressed in PE and circulates as soluble endoglin (sEng) in maternal sera/plasma [39,57]. Circulatory levels are dependent on the severity of PE whereby concentration of sEng is much higher as in PE compared to normal cases [25, 42]. sEng an anti-angiogenic factor, acts as a TGF-β antagonist where it adheres to the TGF-β1 and TGF-β3 receptor and blocks these molecules from binding to the endothelial cell surface, [58] and consequently suppresses the pro-angiogenic and vasodilatory effects of TGF-β1 / TGF-β3 leading to endothelial dysfunction [46].

Soluble endoglin (sEng) acts as an antagonist to TGF-β families by preventing endothelial capillary tube formation and promotes vascular permeability [42]. Overexpression of sEng by adenoviral vector in rats is associated with milder proteinuria and hypertension as compared to overexpression of sFlt-1 alone [25]. Co-expression of sEng and sFlt-1 in rats results in the development of severe proteinuria, hypertension, intrauterine growth restriction, lower platelet counts and elevated LDH similar to that in the HELP syndrome [42]. These data suggest that sEng and sFlt-1 both causes endothelial dysfunction by different mechanism but may act in concert to produce to the clinical syndrome of PE [25].

![Figure 2. Role of pro- and anti-angiogenic factors in endothelial cells](image)

The diagram above shows interaction of membrane glycoprotein (ENG), anti-angiogenic (sFLT-1 & sENG), pro-angiogenic (VEGF & PIGF) and transforming growth factors (TGFβ) with endothelial cells.

Altered levels of circulating angiogenic factors, especially sFlt1, sEng, and PIGF, have been reported to precede the onset of preeclampsia. Excessive levels of circulating anti-endothelial factors produced by the abnormal placentas cause generalized endothelial dysfunction prominent in the maternal syndrome, but the origins of abnormal placentation and its specific role in preeclampsias are still not well understood. Prospective studies to characterize the role of circulating proteins with mediators of endothelial dysfunction, such as sFlt-1, should help shed light on the pathologic mechanisms of the maternal syndrome.

**Acknowledgement**

Authors are grateful to Ministry of Science, Technology and Innovation (MOSTI), Malaysia for supporting this work.
References


58. Luft FC. Soluble endoglin (sEng) joins the soluble fms-like tyrosine kinase (sFlt) receptor as a pre-eclampsia molecule. Nephrol Dial Transplant. 2006; 21: 3052-3054.

Correspondence:
Sekaran Muniandy
Department of Molecular Medicine
Faculty of Medicine
University of Malaya
Kuala Lumpur
Malaysia-50603
Email: sekaran@um.edu.my